secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2023-08-24T23:59:59+00:00
Accession:  0001193125-23-219539
Event type: litigation
Sentiment:  negative
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva settles DOJ price-fixing charges with $225M fine, DPA; avoids federal exclusion
--------------------------------------------------------------------------------

- Teva enters Deferred Prosecution Agreement with DOJ over 2020 price-fixing charges for generic drugs.
- Fine of $225M payable over 5 years: $22.5M/yr 2024-2027, $135M in 2028.
- Teva to donate $50M of two generic products (at wholesale cost) and divest one generic product.
- Admits a single former employee engaged in three instances of collusion with competitors (2013-2015).
- DPA term is 3 years; upon compliance and payment, charges dismissed with prejudice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312523219539/0001193125-23-219539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312523219539/d479429d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-219539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer